

Analysis of the Consequences of the COVID-19 Pandemic on the Continuum of the Care in a Cohort of HIV-Positive Patients Followed in a Single Center of Northern Italy.

Eugenia Quiros-Roldan

Paola Magro (✉ magropao@gmail.com)

<https://orcid.org/0000-0001-7660-161X>

Canio Carriero

Annacarla Chiesa

Issa El Hamad

Elena Tratta

Raffaella Fazio

Beatrice Formenti

Francesco Castelli

Research

Keywords: HIV continuum of care, COVID-19, public health, SARS-CoV-2, follow-up, adherence

Posted Date: July 2nd, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-38253/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published on October 4th, 2020. See the published version at <https://doi.org/10.1186/s12981-020-00314-y>.

Abstract

Background: During the COVID-19 pandemic, hospitals faced increasing pressure, where HIV patients risked to either acquire SARS-CoV-2 and to interrupt the HIV continuum of care.

Methods: retrospective, observational study. We compared the numbers of medical visits performed, antiretroviral drugs dispensed and the number of new HIV diagnosis and of hospitalizations in a cohort of HIV patients followed by the Spedali Civili of Brescia, between the bimester of the COVID-19 pandemic peak and the bimester of October–November 2019.

Results: We observed a reduction in the number of new HIV diagnosis from 6.4 in 2019 to 2.5 per month in 2020, a raise of missed visits from 5% to 8%, a drop in ART dispensation especially for not-protease inhibitors and an increase of hospitalized HIV patients due to COVID-19.

Conclusions: Our experience highlights the importance of a resilient healthcare system and the need to implement new strategies in order to guarantee the continuum of HIV care even in the context of emergency.

Background

Coronavirus disease 2019 (COVID-19) has spread rapidly around the world since the first reports from Wuhan city in China at the end of 2019, and the outbreak was declared as pandemic by WHO on March 12, 2020 (1)). On February 21st, 2020, the first person was reported to be infected with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Lombardy, in Northern Italy. This region rapidly became the first COVID-19 outbreak in Europe. As of May 2nd, 209,328 COVID-19 cases have been confirmed in Italy, where more than one out of three cases (36.7%) were diagnosed in Lombardy, the most populated Region of Italy (2)). From the end of February, hospitals were rapidly overcrowded by COVID-19 patients, and both specialists and non-infectious diseases specialists were reassigned to the new COVID-19 wards to cope with the astonishing number of hospitalized COVID-19 cases. Therefore, most hospitals became COVID-19 hotspots, thus potentially putting outpatients with chronic diseases at risk for nosocomial acquisition of SARS-CoV-2. In addition, hospital personnel faced enormous challenges because of staff reduction due to reassignment to COVID-19 care units and COVID-19 quarantining as consequence of SARS-CoV-2 infection.

The “90–90–90” strategy promoted by UNAIDS is calling for a scaling up of HIV cascade of care to 90% of people living with HIV (PLHIV) diagnosed, 90% linked to care and antiretroviral therapy (ART) and 90% of those patients that adhere to treatment achieving stable viral suppression (3). In the period between March and April 2020, SARS-CoV-2 hit hard on the province of Brescia, Lombardy, which resulted to be the third province in Italy for the number of COVID-19 cases (4). The Spedali Civili of Brescia is the hub hospital for Infectious Diseases in the whole Brescia province, and the only Hospital dedicated to HIV care. In the last period, the majority of the working force specialized on Infectious diseases in our hospital focused on the cure of COVID-19 patients, putting several barriers and challenges to the HIV care continuum. We normally follow almost 4000 HIV-infected patients (5). The onset of the COVID-19 pandemic in our city made urgent and mandatory to institute an emergency response aimed to maintain HIV care delivery, adapting our out-patients clinic to the new and dramatic changes imposed by the pandemic.

Here we describe the continuum of HIV care in our patients, the changes made in order to guarantee medical assistance during these two months and the consequences of the pandemic in our patients in these critical months.

Methods

Study setting

The present retrospective, observational study was conducted at the University Department of Infectious and Tropical Diseases of the Azienda Socio Sanitaria Territoriale (ASST) Spedali Civili of Brescia, Lombardy, Northern Italy. The Spedali Civili General Hospital of Brescia is one of the largest hospitals in Italy, and it is also the reference hospital for the School of Medicine of the University of Brescia. It represents the only tertiary referral center for Infectious Diseases and HIV care of the whole Brescia province (about 1.2 million inhabitants).

Study population

All HIV-positive patients aged 18 years and more followed at our out-patients clinic were included.

From the administrative files, we collected data on i) new HIV diagnosis ii) number of medical visits in our HIV out-patients clinic (scheduled and then performed through in-person assessment or telemedicine, missed or postponed iii) dispensation of antiretroviral (ART) medications and iv) hospitalizations of HIV-positive patients. From the electronic and paper clinical records, we retrieved epidemiological and clinical characteristics including sex, origin country, CD4 + T-cells absolute count, HIVRNA load, antiretroviral therapy (ART), diagnosis of admittance to hospital whether hospitalized.

Normally, chronic HIV-positive patients with stable and efficient ART (HIVRNA < 20 cp/ml for at least six months) and CD4 + T-cells > 500 cell/ μ l are evaluated through blood exams and subsequent medical visit every six months at our clinic. Naïve patients, as well as patients with more complicated medical issues which require a tighter follow-up, are seen more often (6). Antiretroviral drugs are dispensed behind medical prescription every three months by our pharmacy, inside the hospital. During the COVID-19 epidemic, we modified the normal HIV management as explained in Fig. 1. Criteria for telemedicine are reported in Table 1.

Table 1
Criteria for the decision of the medical visit form.

Criteria for the decision of the medical visit form	
• Whether one or more of these criteria was met, the patient was evaluated through a normal medical visit	CD4 + T-cells < 200 cell/µl and/or < 14%
	HIVRNA > 20 cp/ml in the previous examination
• If none of these criteria was present, the visit was performed through telemedicine	Switch to a new ART regimen in the last 6 months
	Decrease of CD4 + T-cells > 25% and/or percentage decrease > 10% in the two previous examinations
	Ongoing treatment with direct anti-viral agents (DAAs) for HCV eradication
	Diagnosis of HIV infection or first contact at our clinic within the last 6 months
	Elevation of liver function tests (LFTs) more than twice the normal values
	Liver cirrhosis
	Unexplained decrease of hemoglobin at last exams
	Chronic kidney disease with creatinine clearance < 60 ml/min or decrease of > 25% in creatinine clearance since the last examination
	Clinical history reporting frailty conditions or high risk of loss at follow-up (e.g. psychiatric comorbidities, active drug addiction, oncologic or hematologic comorbidities; pregnancy; kidney transplants; nursing home residents, patients recently released from prison and/or on house arrest)
	Recent new diagnosis and/or admittance in hospital and/or changes in the therapies for comorbidities
	Previous lost at follow-up since more than one year
	Recent diagnosis of HCV infection, HBV infection, Syphilis new infection or reinfection
	Missed answer to telemedicine call

The study comprises two periods: one before and one during the pandemic. In order to describe the changes in the continuum of care with COVID-19 pandemic, we compared the medical visits and the dispensation of ART medications in our HIV-positive patients occurred between October 1st and November 30th, 2019 and March 1st and April 30th, 2020. We chose October and November 2019 for comparison, because they had similar amounts of festivities, same ARTs available and similar administrative management.

At last, we compared the number of new HIV diagnosis and the number of HIV-positive patients admitted at our hospital during the COVID-19 pandemic and the mean number of those occurred during the year 2019.

Statistical analysis

Categorical variables were described using frequencies and percentages, while continuous variables were described using mean, median, and interquartile range (IQR) values. Means for continuous variables were compared using independent group Student's t-tests when the data were normally distributed and the Mann-Whitney test when they were not. Proportions for categorical variables were compared using the χ^2 test, although Fisher's exact test was used when the data were sparse.

Results

As of December 31st, 2019, a total of 3875 HIV-infected patients (mean age $51,4 \pm 13$ years old) were actively followed in our clinic. Of these, 28% were females and 18.8% non-Italian. Overall, 98.9% were on ART ($n = 3834$), of which 32,1% were assuming an ART regimen that included a protease inhibitor. Viral plasmatic load was < 20 cp/ml in 93% of patients and CD4 + > 350 cells/mm³ in 88.3% (data not shown).

New HIV diagnosis

During 2019, a total of 77 new HIV diagnosis were registered at our center, for a monthly mean of 6,4 new diagnosis. About 20% of all new diagnosis were in females. In the bimester of the COVID-19 pandemic we observed only five patients with a first HIV diagnosis (mean 2,5 new diagnosis per month). Of these, only one occurred in March, while the remaining four were made in April. Three out of five new patients were females (60%), and only one of them was non-Italian (20%). AIDS-defining conditions were present at the moment of HIV diagnosis in two patients (one had Kaposi sarcoma and the second one a non-Hodgkin lymphoma). Among the three remaining, two received HIV diagnosis during routine screenings for pregnancy and the last one in the context of a hospitalization for enteric intussusception. The median CD4 + T-cell count at diagnosis was 236 cell/mm³ (range 12–479 cell/mm³).

Number of medical visits at our HIV out-patients clinic

During the bimesters October-November 2019 and March-April 2020 a total of 1217 and 1162 patients had their visit scheduled at our out-patient HIV clinic, respectively. The overall view of the performed visits is shown in Fig. 2 and in Supplementary material 1. Thanks to the telemedicine program initiated at our clinic at the beginning of the COVID-19 pandemic, a total of 782 (67.3%) patients resulted eligible for this modality and performed their visit through this new useful tool in March and April 2020 (Fig. 2).

Missing visits were significantly higher in the second bimester (8,1% vs 4,9%; $p < 0.01$). As shown in Fig. 3, females tended to skip their scheduled appointment during the pandemic period more than normally (10,6% vs 4,1%, $p < 0.001$).

Not Italian patients showed a similar behavior and were more likely to avoid medical visits in the second bimester (12,9% vs 5,9%, $p < 0.01$). Males registered a trend of decreased presence at visit, even though not statistically significant (5,2% vs 7%, $p = 0.055$) as well as Italian patients (5,2% vs 6,8%, $p = 0.07$).

Dispensation of antiretroviral medications

We have found that the number of patients to whom ART was dispensed during March and April 2020 decreased of -23,1% in comparison with October-November 2019 (Table 2). The highest decrease was observed in non-Italian compared to Italian (-27.4% vs -20.1%) and in females in comparison with males (-23.6% vs -20.5%). When we compared March and April separately with the mean of patients to whom ART was dispensed during the first bimester, we observed a higher drop of drugs dispensation in March (-33.6%) with a trend to normalization in April (-12.6%).

Lastly, we explored potential differences among the number of drug packs dispensed in the two bimesters. We compared the number of drug packs dispensed in March-April 2020 and the mean of packs dispensed between June and December 2019. To this end, we chose to analyze the trends of the most used single tablet regimens (STRs) in our center, including an integrase inhibitor (lamivudine/abacavir/dolutegravir) and a protease inhibitor (PIs) (darunavir/cobicistat/tenofovir alafenamide/emtricitabine) (data not shown). Both STRs registered an average drop of -21.6% and -16.6% respectively for the 2020 bimester in comparison with the second semester of 2019.

Table 2
Trends in antiretroviral dispensation to HIV-positive patients during the bimester of March-April 2020 and October-November 2019.

	Nationality		Sex		Total
	Italian	Non-italian	Males	Females	
% decrease in March-April 2020 compared to October-November 2019*	-20,1%	-27,4%	-20,5%	-23,6%	-23,1%
% decrease in March 2020 compared to the mean of October-November 2019*	-30,0%	-30,6%	-29,1%	-32,7%	-33,6%
% decrease in April 2020 compared to the mean of October-November 2019*	-10,3%	-24,1%	-11,9%	-14,4%	-12,9%
*The percentage was calculated as the difference in the overall number of patients that collected ART between the different study periods.					

Number of HIV-positive patients hospitalized

During 2019, a total of 92 HIV-positive patients were admitted in our ward (7,7 patients/month). Between March and April 2020, 25 HIV-infected patients were admitted to our Infectious Diseases clinic (12,5 patients/months). Among these, 12 patients were hospitalized because of SARS-CoV-2 infection (48%).

Epidemiological, clinical and therapeutic characteristics of each HIV-positive patient admitted for COVID-19 are shown in Table 3.

Table 3
Epidemiological, clinical and therapeutic characteristics of HIV-positive patients hospitalized for COVID-19.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Demographics and baseline HIV status						
Age	62	54	56	52	63	56
Gender	Male	Male	Male	Male	Female	Female
Comorbidities	Hypertension, Cardiovascular disease, Oncological, CKD	Oncological	Hypertension, Cardiovascular disease, Diabetes, HCV	Hematologic Diseases, Glomerulonephritis	Osteopenia	Osteoporosis
Last CD4 (cells per uL)	454	681	616	426	588	886
Last HIV/RNA	< 20	64	< 20	< 20	< 20	< 20
ART regimen before admission	DTG, RPV*	ABC, 3TC, DTG*	TAF, FTC, DTG*	DRV/c, RAL*	ABC, 3TC, DTG*	TAF, FTC, DTG*
Clinical findings on admission						
Symptoms	Right deficit of strength,	Fever	Fever, Cough, Dyspnea	Fever, Cough	None	Fever, Cough
Chest x-ray findings	Interstitial infiltrates	Interstitial infiltrate	Interstitial infiltrates	Interstitial infiltrate	Interstitial infiltrates	Interstitial infiltrates
O2 saturation (%)	98 in ambient air	100 in ambient air	93 in ambient air	96 in ambient air	97 in ambient air	90 in ambient air
SatO2/FiO2 ratio	467	476	443	457	462	429
Severity of the infection	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate
Treatment and outcomes						
Covid-19 treatment	Hydroxychloroquine, DRV/r, Azithromycin	Azithromycin	None	Hydroxychloroquine	Hydroxychloroquine	Hydroxychloroquine DRV/c
Admitted to an ICU	No	No	No	No	No	No
Invasive or non-invasive mechanical ventilation	No	No	No	No	No	No
Length of hospital stay (days)	16	10	9	7	5	12
O2 saturation (%)	97 in ambient air	98 in ambient air	97 in ambient air	99 in ambient air	97 in ambient air	98 in ambient air
SatO2/FiO2 ratio	462	467	462	471	462	467
	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12
Demographics and baseline HIV status						
Age	54	55	55	58	54	57
Gender	Male	Male	Female	Female	Female	Male
Comorbidities	Oncological	-	Diabetes, COPD	Osteopenia, Hypothyroidism	Rheumatoid Arthritis	Oncological

* ART at admission was continued during hospitalization

Abbreviations: 3TC: Lamivudine; ABC: Abacavir; ART: antiretroviral therapy; COPD: Chronic obstructive pulmonary disease; BTG: Bictegravir; CD4: CD4+ T-cells; CKD: Chronic Kidney Disease; DRV/c: Darunavir/cobicistat; DRV/r: Darunavir/ritonavir; DTG: Dolutegravir; FiO2: Fraction of inspired oxygen; FTC: Emtricitabine; HCV: Hepatitis C Virus; ICU: Intensive Care Unit; LPV/r: Lopinavir/ritonavir; RAL: Raltegravir; RPV: Rilpivirine; SatO2: Oxygen saturation; TAF: Tenofovir alafenamide.

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Last CD4 (cells per uL)	265	864	456	406	346	334
Last HIV/RNA	20	20	< 20	-	< 20	20
ART regimen before admission	TAF, FTC, DTG*	TAF, FTC, RPV*	TAF, FTC, RPV*	ABC, 3TC, DTG*	TAF, FTC, BTG*	TAF, FTC, BTG*
Clinical findings on admission						
Symptoms	Dyspnea	Fever, Cough	Fever, Cough	Fever, Cough, Dyspnea,	Fever, Cough	Fever
Chest x-ray findings	Interstitial infiltrates	Interstitial infiltrate	Interstitial infiltrates	Interstitial infiltrates	Interstitial infiltrates	Interstitial infiltrates
O2 saturation (%)	97 in ambient air	95 in ambient air	89 in ambient air	97 in ambient air	100 in FiO2 90%	98 in FiO2 28%
SatO2/FiO2 ratio	462	452	424	462	111	350
Severity of the infection	Moderate	Moderate	Moderate	Moderate	Severe	Moderate
Treatment and outcomes						
Covid-19 treatment	Hydroxychloroquine	Hydroxychloroquine, DRV/c, Tocilizumab	Hydroxychloroquine	Hydroxychloroquine, LPV/r	Hydroxychloroquine, DRV/c, Remdesivir	Hydroxychloroquine
Admitted to an ICU	No	No	No	No	Yes	No
Invasive or non-invasive mechanical ventilation	No	No	No	No	Tracheostomy	No
Length of hospital stay (days)	6	18	11	9	34	11
O2 saturation (%)	96 in ambient air	98 in ambient air	97 in ambient air	97 in ambient air	97 in ambient air	98 in ambient air
SatO2/FiO2 ratio	457	467	462	462	462	467
* ART at admission was continued during hospitalization						
Abbreviations: 3TC: Lamivudine; ABC: Abacavir; ART: antiretroviral therapy; COPD: Chronic obstructive pulmonary disease; BTG: Bictegravir; CD4: CD4+ T-cells; CKD: Chronic Kidney Disease; DRV/c: Darunavir/cobicistat; DRV/r: Darunavir/ritonavir; DTG: Dolutegravir; FiO2: Fraction of inspired oxygen; FTC: Emtricitabine; HCV: Hepatitis C Virus; ICU: Intensive Care Unit; LPV/r: Lopinavir/ritonavir; RAL: Raltegravir; RPV: Rilpivirine; SatO2: Oxygen saturation; TAF: Tenofovir alafenamide.						

The average age was 56 years (IQR, 54-58; range, 52–63 years) and seven (58%) were males. All patients were assuming ART regularly and were virologically suppressed at admission. One patient was prescribed with a regimen including a protease-inhibitor (darunavir-boosted cobicistat). The average number of CD4+ T-cells was 527 cell/mm³ (IQR, 361-665 cell/mm³, Range 265-886 cell/mm³). The average length of hospitalization was 12 days (IQR, 7-15). Hypertension (n=2, 17%), cardiovascular (n=2, 17%) and oncologic diseases (n=4, 33%) and diabetes (n=2, 17%) were the most common coexisting conditions. The great majority of patients reported fever at symptoms onset (n=9, 75%), dry cough (n=7, 58%) and dyspnea (n=3, 25%). At hospital admission, the average SO₂/FiO₂ was 416 (IQR, 425-462; range 111-476). Most of patients (92%) were classified as moderate COVID-19 cases (SO₂/FiO₂ >300mmHg and radiological findings of pneumonia) and only one as severe (SO₂/FiO₂ £300 with radiological pneumonia). Overall, 83% of patients received hydroxychloroquine for COVID-19 treatment (n=10), where seven out of twelve patients (58%) maintained their usual ART during the hospitalization period. None of them died, while one patient required to be transferred to the intensive care unit for critical conditions.

Discussion

The first two months after the pandemic start have produced important changes in the management of HIV-positive patients in our HIV care unit. The main goals during the COVID-19 pandemic have been to both prevent HIV-positive patients and health care professionals from SARS-CoV-2 infection and to maintain an appropriate HIV continuum of care.

Our findings highlight several issues. The first UNAIDS target (90% of all people living with HIV should know their HIV status) (3) is based on HIV testing and it is the first step towards initiation into the HIV care continuum. Our clinic receives patients from a large province with more than 1 million inhabitants, where the incidence of HIV infection is estimated to be one of the highest in Italy, 5.8/100000 compared to 4.7/100000 in the whole country (7). From a public health

perspective, the reduction of the occurrence of new cases is detrimental in order to reduce viral circulation. Promoting HIV testing with early diagnosis represents the essential entry point for both treatment and prevention efforts. Here we show as the COVID-19 pandemic had a negative impact on HIV screening programs in our province. Indeed, we observed a drop in the number of new HIV cases in comparison with the monthly mean of new HIV diagnosis occurred in the 2019 (2.5 vs 6.7 new HIV cases/month, $p = 0.01$). On March 8th, 2020 the Italian government declared the implementation of community containment measures in order to contain the diffusion of SARS-CoV-2 (8), which included social distancing, movement restrictions and quarantine for certain or suspected cases. Predictably, these measures drastically reduced the access to routine HIV testing (9, 10). For a near future, it will be important to organize health services in order to guarantee a safe and continuous access to HIV testing, which is a fundamental health service and a detrimental step towards HIV elimination. Females and non-Italian patients resulted to be less adherent to follow-up visits during the pandemic period. This data needs to be further investigated and addressed. Anyway we believe that it is of fundamental importance to identify the more at-risk populations as auspicated by Hargreaves *et al* (11), in order to better address their needs and behaviors.

The second target (3), (90% of all people with HIV diagnosis should be maintained linked to HIV care) is based in offering and maintaining HIV care in all patients. Soon, hospital visits may be restricted again because of implementation of city lockdowns or traffic controls. From the beginning of March, we adopted the telemedicine tool with the purpose of avoiding the interruption of the continuum of HIV care. We performed structured phone interviews, where the physician together with collecting information about clinical status and ART adherence, also shared laboratory results and future appointments with HIV-positive patients. Telemedical consultations have helped to solve the otherwise unmanageable discrepancy between the *#stayathome* strategy and the need of a continuous medical assistance as also Ridgway *et al* experienced (12). Our preliminary experience shows that a large proportion of patients (67,3%) is eligible for a telemedical appointment. In the next years, we may think of this strategy for semesterly evaluation of stable patients. Moreover, this new tool may be helpful to avoid stigma related to be seen in an Infectious Diseases clinic, to decrease the loss of hours of work for medical visits and to reduce the illness perception. Nonetheless, we recommend that more complex cases keep on being considered for in-person medical evaluation and more often than every six months. Anyway, for a more comprehensive understanding of the efficacy of this approach and its impact on HIV care, we will need to evaluate HIV plasmatic suppression in the months to come.

The last target (3), (90% of HIV-positive patients with suppressed viral plasmatic loads) is based in assuring antiretroviral therapy to HIV-positive patients and in reinforcing adherence to ART. According to Italian regulations, HIV-positive patients need to collect their ART at the hospital pharmacy either personally or through a person authorized with a written approval form. Immediately after the beginning of the outbreak, many local charities began to offer home delivery services for ART medications through volunteers, in order to avoid patients exposure. At the beginning this service was not homogenous, relying on local associations or individual initiatives (e.g. municipal police, veterans, local charities, local Red Cross committee, etc.), while at the end of March, this service was coordinated on a national basis, and supported by Red Cross volunteers. In fact, we observed that although the mean decrease during the study period was - 23% compared to 2019, in March the decrease reached - 33,6%, when in April this trend tended to normalize (-12,6%). Once again, we will need to wait to better understand the consequences of this period on ART adherence and HIV replication.

Because many HIV-positive patients contacted us asking whether protease inhibitors would have been protective against SARS-CoV-2 infection (13–16), we analyzed the changes on the collection of STRs including protease inhibitors (darunavir/cobicistat/tenofovir alafenamide/emtricitabine) and STRs not including PIs (lamivudine/abacavir/dolutegravir) at our pharmacy. What we observed is that STRs including PIs had a smaller average drop than STR including integrase inhibitors (16,6% vs 21,6%, $p < 0.05$). Although we cannot assert whether patients on PIs have been more compliant to ART collection because of the possible effect of these drugs on COVID-19, we think that this data is interesting for it to be pointed out.

Lastly, we described the clinical consequences of SARS-CoV-2 infection in our cohort. We recorded almost a doubling in the number of hospitalizations in HIV-positive patients in comparison with 2019, with a mean of 12,5 patients per month in the second bimester in comparison with 7,6 patients per month in the first. This increase can be ascribed to SARS-CoV-2 infection in HIV-positive patients: indeed, on average, we recorded six HIV/SARS-CoV-2 coinfections per month in 2020. Overall, we managed few cases of HIV/SARS-CoV-2 coinfections. Most of them were admitted with a moderate COVID-19 disease and had optimal outcomes, despite a higher average age and a higher proportion of patients with comorbidities (75%) in comparison with other cohorts (17, 18). Besides, all patients, except three, had CD4 + T-cells > 350/mm³, indicating no severe immune deficiency. As more data were coming out for the efficacy of PIs against SARS-CoV-2 in vivo (19), half of our patients maintained their usual ART and did not switch to a PI during the time of hospitalization. Of those hospitalized, only one patient was prescribed chronically with darunavir/cobicistat and was virosuppressed at admittance. Our observation, although very modest, may add evidence for a lack of a protective role of darunavir against SARS-CoV-2 (20), while more robust evidences are awaited (21). At last, our experience does not support the idea of an excess of morbidity and mortality among PLWH with viral suppression affected by COVID-19 pneumonia. Moreover, we agree with the recent suggestion from Jones *et al* (22) of not modifying ART in order to attempt to treat SARS-CoV-2 infection.

Our study has important limitations. First, this is a retrospective study without follow-up, therefore it is not possible to ascertain the consequences and the efficacy of our strategies on the last 90 of our strategy (90% of all people receiving antiretroviral therapy with viral suppression). Moreover, the number of hospitalized HIV-positive patients may be small to offer a comprehensive understanding of COVID-19 disease in HIV-positive patients. About this, we may have "lost" some HIV/SARS-CoV-2 coinfections, due to eventual hospitalizations in hospitals other than ours. It must be said anyway, that HIV patients normally tend to be centralized and hospitalized in our ward.

Strength of this study is to have analyzed the main falls in the continuum of HIV care in our area during the emergency period. Now, we have learnt that telemedicine and home delivery services for ART medications are useful and powerful tools. Anyway, our data also emphasize the need to detect the populations at high risk for HIV care attrition (in our case, females and non-Italian patients) and to implement effective retention tools focused on these. We fell in maintaining high levels of routine HIV screening, which is crucial for early diagnosis and for reduction of viral circulation. Therefore, we learned that we have to keep on offering valid alternatives for HIV screening, where several health-care services and other community-based organizations were closed in this

period due to the COVID-19 emergency. Moreover, in-person evaluations need to be maintained for those cases which are considered clinically more complicated or more at risk of loss.

Conclusions

Even though we cannot have definitive data in such a short period, our preliminary impressions are that telemedicine can be a useful tool, which can make communications with some group of patients who are already engaged on the continuum of care available and easier. This strategy may be extremely useful during pandemic times, but also beyond them and may be further implemented, for example through video calls. HIV testing services and strategies need to be supported and promoted even in critical periods, in the near future. Females and non-Italian patients are an especially at risk population for loss at follow-up, at least in the short period, so that special attention should be paid to these population in order to make them feel safe and to let them understand the fundamental importance of a continuous adherence to ART even during in emergency periods. Unfortunately, we may say, it seems like that we need to adapt our HIV care services to emergency settings. We hope that the strategy that we found will result effective in the near future, and that our experience may help to open a debate on the best ways to manage the HIV-positive population in this new reality.

List Of Abbreviations

3TC: Lamivudine;

ABC: Abacavir;

ART: antiretroviral therapy;

COPD: Chronic obstructive pulmonary disease;

COVID-19: Coronavirus Disease 2019

BTG: Bictegavir; CD4: CD4+ T-cells;

CKD: Chronic Kidney Disease;

DRV/c: Darunavir/cobicistat;

DRV/r: Darunavir/ritonavir;

DTG: Dolutegravir;

FiO₂: Fraction of inspired oxygen;

FTC: Emtricitabine;

HCV: Hepatitis C Virus;

HIV: Human Immunodeficiency Virus

ICU: Intensive Care Unit;

LPV/r: Lopinavir/ritonavir;

RAL: Raltegravir;

RPV: Rilpivirine;

SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2

SatO₂: Oxygen saturation;

TAF: Tenofovir alafenamide.

Declarations

Ethics approval and consent to participate

This study was conducted accordingly to the Declaration of Helsinki and the principles of Good Clinical Practices (GCP). As this study had a retrospective design and was based on routinely collected data, patients informed consent was not required according to the Italian Law (Italian Guidelines for classification and conduction of observational studies, established by the Italian Drug Agency, "Agenzia Italiana del Farmaco – AIFA" on March 20, 2008). Moreover, for this study we used the general authorization of the Italian Guarantor for the use of retrospective demographical and clinical data, which have been treated according to present laws.

Consent for publication

See above

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

FC reports acting as a principle investigator of company-sponsored clinical trials in the field of HIV infection (ViiV Healthcare, GlaxoSmithKline, Gilead Sciences and Janssen – Cilag). EQR. received travel grants from Bristol-Myers Squibb, Gilead Sciences, ViiV Healthcare, Janssen-Cilag Merck Sharp & Dohme and consultancy fees from Janssen -Cilag, ViiV Healthcare and Merck Sharp & Dohme. The other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Funding

Not applicable

Authors contribution

EQR designed and wrote the study; PM, BF, CC, ET, RF collected data; PM and BF helped to write the manuscript; all authors read and revised critically the manuscript and accepted it.

Acknowledgements

We want to dedicate this study to all those patients who have died from SARS-CoV-2 infection. We hope that our work may be useful in the fight against this new epidemic.

References

1. WHO announces COVID-19 outbreak a pandemic (Internet). 2020 (cited 2020 May 2). Available from: <http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/3/who-announces-covid-19-outbreak-a-pandemic>. Last accessed: May 2020.
2. Covid-19 - Situazione in Italia (Internet). 2020 (cited 2020 May 2). Available from: <http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?area=nuovoCoronavirus&id=5351&lingua=italiano&menu=vuoto>. Last accessed: May 2020.
3. UN Joint Programme on HIV/AIDS (UNAIDS). 90-90-90. An ambitious treatment target to help end the AIDS epidemic. United Nations. 2014. Available at: <https://www.unaids.org/en/resources/909090>. Last accessed: May 2020.
4. Covid 19 - Ripartizione dei contagiati per provincia (Internet). 2020 (cited 2020 May 2). Available from: http://www.salute.gov.it/imgs/C_17_notizie_4659_1_file.pdf. Last accessed: May 2020.
5. Comelli A, Izzo I, Donato F, Celotti A, Foca E, Pezzoli C, et al. Disengagement and reengagement of HIV continuum of care in a single center cohort in northern Italy. *HIV Res Clin Pract*. 2019 Feb;20(1):1–11.
6. Regione Lombardia Direzione Generale Welfare. Percorso diagnostico-terapeutico assistenziale (PDTA) del paziente affetto da malattia HIV/AIDS. Anno 2019. (Internet). 2019. Available from: <http://www.simit.org/medias/1505-pdta-hiv-2019.pdf>
7. Istituto Superiore di Sanità. Aggiornamento delle nuove diagnosi di infezione da HIV e dei casi di AIDS in Italia al 31 dicembre 2018. Available at: http://old.iss.it/binary/publ/cont/AGGIORNAMENTO_HIV_2018.pdf. Last accessed: May 2020.
8. DECRETO DEL PRESIDENTE DEL CONSIGLIO DEI MINISTRI 8 marzo 2020. Ulteriori disposizioni attuative del decreto-legge 23 febbraio 2020, n. 6, recante misure urgenti in materia di contenimento e gestione dell'emergenza epidemiologica da COVID-19. (20A01522) (Internet). Available from: <https://www.gazzettaufficiale.it/eli/id/2020/03/08/20A01522/sg>. Last accessed: May 2020.
9. Jiang H, Zhou Y, Tang W. Maintaining HIV care during the COVID-19 pandemic. *Lancet HIV* (Internet). Available from: [https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018\(20\)30105-3/fulltext](https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(20)30105-3/fulltext)
10. Pinto RM, Park S. COVID-19 Pandemic Disrupts HIV Continuum of Care and Prevention: Implications for Research and Practice Concerning Community-Based Organizations and Frontline Providers [published online ahead of print, 2020 Apr 28]. *AIDS Behav*. 2020;1-4. doi:10.1007/s10461-020-02893-3
11. Hargreaves J, Davey C, the Group for lessons from pandemic HIV prevention for the COVID-19 response. Three lessons for the COVID-19 response from pandemic HIV. *lancet HIV*. 2020;7.

12. Ridgway, J.P., Schmitt, J., Friedman, E. et al. HIV Care Continuum and COVID-19 Outcomes Among People Living with HIV During the COVID-19 Pandemic, Chicago, IL. *AIDS Behav* (2020). <https://doi.org/10.1007/s10461-020-02905-2>
13. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Biosci* 2020 Mar 16;14(1):69-71. doi: 10.5582/bst.2020.01020. Epub 2020 Jan 28. PubMed PMID: 31996494.
14. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. *Acta Pharm Sin B* (Internet). 2020 Feb 27;10.1016/j.apsb.2020.02.008. Available from: <https://pubmed.ncbi.nlm.nih.gov/32292689>
15. Liu C, Zhou Q, Li Y, Garner L V, Watkins SP, Carter LJ, et al. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. *ACS Cent Sci* (Internet). 2020/03/12. 2020 Mar 25;6(3):315–31. Available from: <https://pubmed.ncbi.nlm.nih.gov/32226821>
16. Beck BR, Shin B, Choi Y, Park S, Kang K. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. *Comput Struct Biotechnol J* (Internet). 2020 Mar 30;18:784–90. Available from: <https://pubmed.ncbi.nlm.nih.gov/32280433>
17. Blanco JL, Ambrosioni J, Garcia F, Martínez E, Soriano A, Mallolas J, Miro JM; COVID-19 in HIV Investigators. COVID-19 in patients with HIV: clinical case series. *Lancet HIV*. 2020 May;7(5):e314-e316. doi: 10.1016/S2352-3018(20)30111-9. Epub 2020 Apr 15. PubMed PMID: 32304642; PubMed Central PMCID: PMC7159872.
18. Gervasoni C, Meraviglia P, Riva A, Giacomelli A, Oreni L, Minisci D et al. Clinical features and outcomes of HIV patients with coronavirus disease 2019. *Clin Infect Dis*. 2020 May 14. pii: ciaa579. doi: 10.1093/cid/ciaa579. (Epub ahead of print) PubMed PMID: 32407467.
19. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med* (Internet). 2020 Mar 18;382(19):1787–99. Available from: <https://doi.org/10.1056/NEJMoa2001282>
20. Riva A, Conti F, Bernacchia D, Pezzati L, Sollima S, Merli S, Siano M, Lupo A, Rusconi S, Cattaneo D, Gervasoni C. Darunavir does not prevent SARS-CoV-2 infection in HIV patients. *Pharmacol Res*. 2020 Apr 20;157:104826. doi: 10.1016/j.phrs.2020.104826. (Epub ahead of print) PubMed PMID: 32325127; PubMed Central PMCID: PMC7194792.
21. Lu H. Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19 (DC-COVID-19) (Internet). Available from: <https://clinicaltrials.gov/ct2/show/NCT04252274#wrapper>. Last accessed: May 2020.
22. Jones R, Nelson M, Bracchi M, Asboe D, Boffito M. COVID-19 in patients with HIV. *Lancet HIV*. 2020 May 14. pii: S2352-3018(20)30139-9. doi: 10.1016/S2352-3018(20)30139-9. (Epub ahead of print) PubMed PMID: 32416771.

Figures





Figure 1

Algorithm for the decision of medical visit modality during the COVID-19 pandemic.

A. October-November 2019



B. March-april 2020




Figure 2

A. Overall view of the percentage of patients that performed their scheduled medical visit in the first bimester; B. Overall view of the percentage of patients that performed their scheduled medical visit (both through telemedicine and through in-person evaluation) in the second bimester.




Figure 3

Proportion of patients that performed the scheduled medical visit in the first bimester in comparison with the second bimester according to sex and nationality.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [CoverLetter.docx](#)
- [Supplementarymaterial1.docx](#)